Companion Diagnostic Devices Market , 2012-2023
Global Companion Diagnostic Devices Market
Companion diagnostics are medical devices, often an in-vitro device and provides the information that essential for safe and effective use of the corresponding drug or biotechnology product. Companion diagnostics are often developed along with drugs to aid in selecting or excluding the patient groups for the treatment with particular drug on basis of their biological characters. Companion diagnostics are developed based on biomarkers technology to predict response or severe toxicity of the drugs or biotechnological compounds. Companion diagnostics are majorly used in oncology area.
Some of the factors like improved efficacy and safety profiles of drugs, Accelerated drug regulatory approvals, reduced healthcare expenditure and drug development costs, increasing partnerships between market players, government organizations and other research firms over the use of co diagnostics, emergence of new pharmaceuticals and diagnostics are driving the growth of the global companion diagnostics market. However, due to the regulatory uncertainty, complex clinical trial procedures and intellectual property issues in certain areas are the few issues which are restraining the growth of the global companion diagnostics devices market.
Global companion diagnostic devices are segmented on the basis of application, technology, end user and geographical region.
Based on the application, global companion diagnostic devices are segmented as:
Geographically, companion diagnostic devices market is segmented into five regions: North America, Europe, Latin America, Asia-Pacific and Middle East & Africa. North America expected to be major market for companion diagnostics owing to growth innovative technologies in biomarkers, increase in R&D investment in the region. Asia-Pacific and Europe are expected to grow at a significant rate owing to large patent and consumer base, increasing government initiatives developing healthcare infrastructure, and growing disposable income.
Some of the players in companion diagnostic devices market are F. Hoffmann-La Roche Ltd.(Switzerland), Qiagen Ltd. (Germany), ARUP Laboratories (U.S.), Abbott Laboratories (U.S.), Biogenex Laboratories, Inc. (U.S), Thermo Fisher Scientific (U.S), Ventana Medical Systems Inc. (U.S), Myriad Genetics Inc. (U.S), and Danaher (U.S) and others.
In June 2015, Ventana Medical Systems, Inc. (RocheGroup) has received USFDA approval for its ventana alk cdx assay, companion diagnostic to aid in the identification of patients for, xalkori (crizotinib) (Pfizer’s FDA approved targeted therapy)
In July 2014, AstraZeneca collaborated with Roche to develop a plasma-based companion diagnostic test to support azd9291, for non-small-cell lung cancer
In 2014, Ventana Medical Systems, Inc., collaborated with ImmunoGen, Inc. to develop biomarker assays and a companion diagnostic immunohistochemistry test (IHC) for one ImmunoGen’s product candidates
Companion diagnostics are medical devices, often an in-vitro device and provides the information that essential for safe and effective use of the corresponding drug or biotechnology product. Companion diagnostics are often developed along with drugs to aid in selecting or excluding the patient groups for the treatment with particular drug on basis of their biological characters. Companion diagnostics are developed based on biomarkers technology to predict response or severe toxicity of the drugs or biotechnological compounds. Companion diagnostics are majorly used in oncology area.
Some of the factors like improved efficacy and safety profiles of drugs, Accelerated drug regulatory approvals, reduced healthcare expenditure and drug development costs, increasing partnerships between market players, government organizations and other research firms over the use of co diagnostics, emergence of new pharmaceuticals and diagnostics are driving the growth of the global companion diagnostics market. However, due to the regulatory uncertainty, complex clinical trial procedures and intellectual property issues in certain areas are the few issues which are restraining the growth of the global companion diagnostics devices market.
Global companion diagnostic devices are segmented on the basis of application, technology, end user and geographical region.
Based on the application, global companion diagnostic devices are segmented as:
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Urology
- Melanoma
- Gastric Cancer
- Others
- Immunohistochemistry
- Molecular Diagnostics
- In-situ Hybridization
- FISH
- CISH
- Real-Time PCR
- Gene Sequencing
- Hospitals
- Diagnostic Centres
- Others
Geographically, companion diagnostic devices market is segmented into five regions: North America, Europe, Latin America, Asia-Pacific and Middle East & Africa. North America expected to be major market for companion diagnostics owing to growth innovative technologies in biomarkers, increase in R&D investment in the region. Asia-Pacific and Europe are expected to grow at a significant rate owing to large patent and consumer base, increasing government initiatives developing healthcare infrastructure, and growing disposable income.
Some of the players in companion diagnostic devices market are F. Hoffmann-La Roche Ltd.(Switzerland), Qiagen Ltd. (Germany), ARUP Laboratories (U.S.), Abbott Laboratories (U.S.), Biogenex Laboratories, Inc. (U.S), Thermo Fisher Scientific (U.S), Ventana Medical Systems Inc. (U.S), Myriad Genetics Inc. (U.S), and Danaher (U.S) and others.
In June 2015, Ventana Medical Systems, Inc. (RocheGroup) has received USFDA approval for its ventana alk cdx assay, companion diagnostic to aid in the identification of patients for, xalkori (crizotinib) (Pfizer’s FDA approved targeted therapy)
In July 2014, AstraZeneca collaborated with Roche to develop a plasma-based companion diagnostic test to support azd9291, for non-small-cell lung cancer
In 2014, Ventana Medical Systems, Inc., collaborated with ImmunoGen, Inc. to develop biomarker assays and a companion diagnostic immunohistochemistry test (IHC) for one ImmunoGen’s product candidates
1. EXECUTIVE SUMMARY
2. GLOBAL COMPANION DIAGNOSTIC DEVICES MARKET INTRODUCTION
2.1. Global Companion Diagnostic Devices Market – Taxonomy
2.2. Global Companion Diagnostic Devices Market –Definitions
2.2.1. Technology
2.2.2. Application
3. GLOBAL COMPANION DIAGNOSTIC DEVICES MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Companion Diagnostic Devices Market Dynamic Factors - Impact Analysis
4. GLOBAL COMPANION DIAGNOSTIC DEVICES MARKET ANALYSIS, 2012 – 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. GLOBAL COMPANION DIAGNOSTIC DEVICES MARKET, BY TECHNOLOGY, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
5.1. Immunohistochemistry
5.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Molecular Diagnostics
5.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. In-situ Hybridization
5.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. FISH
5.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. CISH
5.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Real-Time PCR
5.6.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Gene Sequencing
5.7.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
6. GLOBAL COMPANION DIAGNOSTIC DEVICES MARKET, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
6.1. Breast Cancer
6.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Colorectal Cancer
6.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Lung Cancer
6.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Urology
6.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Melanoma
6.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Gastric Cancer
6.6.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
6.7. Others
6.7.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.7.3. Market Opportunity Analysis
7. GLOBAL COMPANION DIAGNOSTIC DEVICES MARKET, BY END USER, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
7.1. Hospitals
7.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Diagnostic Centers
7.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Others
7.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. GLOBAL COMPANION DIAGNOSTIC DEVICES MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
8.1. North America
8.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Companion Diagnostic Devices Market - Opportunity Analysis Index, By Technology, By Application, By End User, and Region, 2017 – 2023
9. NORTH AMERICA COMPANION DIAGNOSTIC DEVICES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
9.1. Technology Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Immunohistochemistry
9.1.2. Molecular Diagnostics
9.1.3. In-situ Hybridization
9.1.4. FISH
9.1.5. CISH
9.1.6. Real-Time PCR
9.1.7. Gene Sequencing
9.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Breast Cancer
9.2.2. Colorectal Cancer
9.2.3. Lung Cancer
9.2.4. Urology
9.2.5. Melanoma
9.2.6. Gastric Cancer
9.2.7. Others
9.3. End User Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.3.1. Hospitals
9.3.2. Diagnostic Centres
9.3.3. Others
9.4. Country Analysis 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Companion Diagnostic Devices Market - Opportunity Analysis Index, By Technology, By Application, By End User, and Country, 2017 – 2023
9.6. North America Companion Diagnostic Devices Market Dynamics – Trends
10. EUROPE COMPANION DIAGNOSTIC DEVICES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
10.1. Technology Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Immunohistochemistry
10.1.2. Molecular Diagnostics
10.1.3. In-situ Hybridization
10.1.4. FISH
10.1.5. CISH
10.1.6. Real-Time PCR
10.1.7. Gene Sequencing
10.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Breast Cancer
10.2.2. Colorectal Cancer
10.2.3. Lung Cancer
10.2.4. Urology
10.2.5. Melanoma
10.2.6. Gastric Cancer
10.2.7. Others
10.3. End User Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Hospitals
10.3.2. Diagnostic Centres
10.3.3. Others
10.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Companion Diagnostic Devices Market - Opportunity Analysis Index, By Technology, By Application, By End User, and Country, 2017 – 2023
10.6. Europe Companion Diagnostic Devices Market Dynamics – Trends
11. ASIA-PACIFIC COMPANION DIAGNOSTIC DEVICES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
11.1. Technology Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Immunohistochemistry
11.1.2. Molecular Diagnostics
11.1.3. In-situ Hybridization
11.1.4. FISH
11.1.5. CISH
11.1.6. Real-Time PCR
11.1.7. Gene Sequencing
11.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Breast Cancer
11.2.2. Colorectal Cancer
11.2.3. Lung Cancer
11.2.4. Urology
11.2.5. Melanoma
11.2.6. Gastric Cancer
11.2.7. Others
11.3. End User Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Hospitals
11.3.2. Diagnostic Centres
11.3.3. Others
11.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Companion Diagnostic Devices Market - Opportunity Analysis Index, By Technology, By Application, By End User, and Country, 2017 – 2023
11.6. Asia-Pacific Companion Diagnostic Devices Market Dynamics – Trends
12. LATIN AMERICA COMPANION DIAGNOSTIC DEVICES MARKET ANALYSIS, 2012 - 2012 - 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
12.1. Technology Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Immunohistochemistry
12.1.2. Molecular Diagnostics
12.1.3. In-situ Hybridization
12.1.4. FISH
12.1.5. CISH
12.1.6. Real-Time PCR
12.1.7. Gene Sequencing
12.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Breast Cancer
12.2.2. Colorectal Cancer
12.2.3. Lung Cancer
12.2.4. Urology
12.2.5. Melanoma
12.2.6. Gastric Cancer
12.2.7. Others
12.3. End User Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Hospitals
12.3.2. Diagnostic Centres
12.3.3. Others
12.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Venezuela
12.4.5. Rest of Latin America
12.5. Latin America Companion Diagnostic Devices Market - Opportunity Analysis Index, By Technology, By Application, By End User, and Country, 2017 – 2023
12.6. Latin America Companion Diagnostic Devices Market Dynamics – Trends
13. MIDDLE EAST AND AFRICA COMPANION DIAGNOSTIC DEVICES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
13.1. Technology Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Immunohistochemistry
13.1.2. Molecular Diagnostics
13.1.3. In-situ Hybridization
13.1.4. FISH
13.1.5. CISH
13.1.6. Real-Time PCR
13.1.7. Gene Sequencing
13.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Breast Cancer
13.2.2. Colorectal Cancer
13.2.3. Lung Cancer
13.2.4. Urology
13.2.5. Melanoma
13.2.6. Gastric Cancer
13.2.7. Others
13.3. End User Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.3.1. Hospitals
13.3.2. Diagnostic Centres
13.3.3. Others
13.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Companion Diagnostic Devices Market - Opportunity Analysis Index, By Technology, By End User, By Application, and Country, 2017 – 2023
13.6. MEA Companion Diagnostic Devices Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. F. Hoffmann-La Roche Ltd.(Switzerland)
14.2.2. Qiagen Ltd. (Germany)
14.2.3. ARUP Laboratories (U.S.)
14.2.4. Abbott Laboratories (U.S.)
14.2.5. Biogenex Laboratories, Inc. (U.S)
14.2.6. Thermo Fisher Scientific (U.S)
14.2.7. Ventana Medical Systems Inc. (U.S)
14.2.8. Myriad Genetics Inc. (U.S)
14.2.9. Danaher (U.S)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYM
2. GLOBAL COMPANION DIAGNOSTIC DEVICES MARKET INTRODUCTION
2.1. Global Companion Diagnostic Devices Market – Taxonomy
2.2. Global Companion Diagnostic Devices Market –Definitions
2.2.1. Technology
2.2.2. Application
3. GLOBAL COMPANION DIAGNOSTIC DEVICES MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Companion Diagnostic Devices Market Dynamic Factors - Impact Analysis
4. GLOBAL COMPANION DIAGNOSTIC DEVICES MARKET ANALYSIS, 2012 – 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. GLOBAL COMPANION DIAGNOSTIC DEVICES MARKET, BY TECHNOLOGY, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
5.1. Immunohistochemistry
5.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Molecular Diagnostics
5.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. In-situ Hybridization
5.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. FISH
5.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. CISH
5.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Real-Time PCR
5.6.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Gene Sequencing
5.7.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
6. GLOBAL COMPANION DIAGNOSTIC DEVICES MARKET, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
6.1. Breast Cancer
6.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Colorectal Cancer
6.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Lung Cancer
6.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Urology
6.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Melanoma
6.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Gastric Cancer
6.6.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
6.7. Others
6.7.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.7.3. Market Opportunity Analysis
7. GLOBAL COMPANION DIAGNOSTIC DEVICES MARKET, BY END USER, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
7.1. Hospitals
7.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Diagnostic Centers
7.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Others
7.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. GLOBAL COMPANION DIAGNOSTIC DEVICES MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
8.1. North America
8.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Companion Diagnostic Devices Market - Opportunity Analysis Index, By Technology, By Application, By End User, and Region, 2017 – 2023
9. NORTH AMERICA COMPANION DIAGNOSTIC DEVICES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
9.1. Technology Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Immunohistochemistry
9.1.2. Molecular Diagnostics
9.1.3. In-situ Hybridization
9.1.4. FISH
9.1.5. CISH
9.1.6. Real-Time PCR
9.1.7. Gene Sequencing
9.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Breast Cancer
9.2.2. Colorectal Cancer
9.2.3. Lung Cancer
9.2.4. Urology
9.2.5. Melanoma
9.2.6. Gastric Cancer
9.2.7. Others
9.3. End User Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.3.1. Hospitals
9.3.2. Diagnostic Centres
9.3.3. Others
9.4. Country Analysis 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Companion Diagnostic Devices Market - Opportunity Analysis Index, By Technology, By Application, By End User, and Country, 2017 – 2023
9.6. North America Companion Diagnostic Devices Market Dynamics – Trends
10. EUROPE COMPANION DIAGNOSTIC DEVICES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
10.1. Technology Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Immunohistochemistry
10.1.2. Molecular Diagnostics
10.1.3. In-situ Hybridization
10.1.4. FISH
10.1.5. CISH
10.1.6. Real-Time PCR
10.1.7. Gene Sequencing
10.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Breast Cancer
10.2.2. Colorectal Cancer
10.2.3. Lung Cancer
10.2.4. Urology
10.2.5. Melanoma
10.2.6. Gastric Cancer
10.2.7. Others
10.3. End User Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Hospitals
10.3.2. Diagnostic Centres
10.3.3. Others
10.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Companion Diagnostic Devices Market - Opportunity Analysis Index, By Technology, By Application, By End User, and Country, 2017 – 2023
10.6. Europe Companion Diagnostic Devices Market Dynamics – Trends
11. ASIA-PACIFIC COMPANION DIAGNOSTIC DEVICES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
11.1. Technology Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Immunohistochemistry
11.1.2. Molecular Diagnostics
11.1.3. In-situ Hybridization
11.1.4. FISH
11.1.5. CISH
11.1.6. Real-Time PCR
11.1.7. Gene Sequencing
11.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Breast Cancer
11.2.2. Colorectal Cancer
11.2.3. Lung Cancer
11.2.4. Urology
11.2.5. Melanoma
11.2.6. Gastric Cancer
11.2.7. Others
11.3. End User Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Hospitals
11.3.2. Diagnostic Centres
11.3.3. Others
11.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Companion Diagnostic Devices Market - Opportunity Analysis Index, By Technology, By Application, By End User, and Country, 2017 – 2023
11.6. Asia-Pacific Companion Diagnostic Devices Market Dynamics – Trends
12. LATIN AMERICA COMPANION DIAGNOSTIC DEVICES MARKET ANALYSIS, 2012 - 2012 - 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
12.1. Technology Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Immunohistochemistry
12.1.2. Molecular Diagnostics
12.1.3. In-situ Hybridization
12.1.4. FISH
12.1.5. CISH
12.1.6. Real-Time PCR
12.1.7. Gene Sequencing
12.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Breast Cancer
12.2.2. Colorectal Cancer
12.2.3. Lung Cancer
12.2.4. Urology
12.2.5. Melanoma
12.2.6. Gastric Cancer
12.2.7. Others
12.3. End User Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Hospitals
12.3.2. Diagnostic Centres
12.3.3. Others
12.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Venezuela
12.4.5. Rest of Latin America
12.5. Latin America Companion Diagnostic Devices Market - Opportunity Analysis Index, By Technology, By Application, By End User, and Country, 2017 – 2023
12.6. Latin America Companion Diagnostic Devices Market Dynamics – Trends
13. MIDDLE EAST AND AFRICA COMPANION DIAGNOSTIC DEVICES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
13.1. Technology Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Immunohistochemistry
13.1.2. Molecular Diagnostics
13.1.3. In-situ Hybridization
13.1.4. FISH
13.1.5. CISH
13.1.6. Real-Time PCR
13.1.7. Gene Sequencing
13.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Breast Cancer
13.2.2. Colorectal Cancer
13.2.3. Lung Cancer
13.2.4. Urology
13.2.5. Melanoma
13.2.6. Gastric Cancer
13.2.7. Others
13.3. End User Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.3.1. Hospitals
13.3.2. Diagnostic Centres
13.3.3. Others
13.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Companion Diagnostic Devices Market - Opportunity Analysis Index, By Technology, By End User, By Application, and Country, 2017 – 2023
13.6. MEA Companion Diagnostic Devices Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. F. Hoffmann-La Roche Ltd.(Switzerland)
14.2.2. Qiagen Ltd. (Germany)
14.2.3. ARUP Laboratories (U.S.)
14.2.4. Abbott Laboratories (U.S.)
14.2.5. Biogenex Laboratories, Inc. (U.S)
14.2.6. Thermo Fisher Scientific (U.S)
14.2.7. Ventana Medical Systems Inc. (U.S)
14.2.8. Myriad Genetics Inc. (U.S)
14.2.9. Danaher (U.S)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYM
